Celltrion Files For Korea Approval Of Herceptin Biosimilar
This article was originally published in PharmAsia News
Amid M&A talks and expectations for imminent European approval of a Remicade biosimilar, Celltrion becomes the first company to file for regulatory approval of a biosimilar of Roche’s blockbuster breast cancer therapy trastuzumab.
You may also be interested in...
Kadcyla Positioned For Wide Use In Metastatic Breast Cancer
Roche is set to launch T-DM1 at the price of $9,800 a month, similar to cost of the preferred first-line regimen, which includes a combination of its own Perjeta and Herceptin. Drug was tested mostly in second-line HER-2 positive mBC, but labeling allows first-line treatment in a subset of patients at high risk.
Korea Biosimilars Leader Celltrion Shrugs Off Accounting Controversy, Focuses on Growth
SEOUL - Despite controversy over an accounting issue raised recently by local media, analysts remain bullish about Korea biosimilars front-runner Celltrion, Inc., which is gearing up to launch two biosimilars next year
Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma
SEOUL - Seo Jung-Jin, CEO of South Korea's biosimilar front-runner Celltrion, Inc. said his company isn't looking to establish additional sales and distribution partnerships with Big Pharma